stockrow
Monday 9 November 2026
Export CAMP’s income statement to Excel — free account
CAMP4 Therapeutics Corporation
CAMPCAMP4 Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, up 436.5% from fiscal 2024.
- Revenue
- +138.9%
- EPS
- +32.7%
- Free cash flow
- +20.4%
Quarter to September 2026, against a year earlier
4.06
0.34
+9.14%
Follow CAMP
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 0 | 1 | 3 | 5 | +216.1% | 6 | 4 | 2 | (23.5%) | |
| Gross margin, % | — | — | — | — | — | — | — | 100.00 | 100.00 | 100.00 | 100.00 | 0.0 pt | ||||||
| EBT | — | — | — | — | — | — | (44) | (49) | (52) | (80) | (121) | +22.1% | ||||||
| EBT margin, % | — | — | — | — | — | — | 0.00 | (14,083.14) | (7,943.40) | (2,298.54) | (2,276.33) | (2,298.5) pt | ||||||
| Net income | — | — | — | — | — | — | (44) | (49) | (52) | (80) | (121) | +22.1% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.89 | 0.14 | 0.12 | 0.07 | n/m | |||||
| Earnings | — | — | — | — | — | — | (141.51) | (124.79) | (11.04) | (2.65) | (2.02) | (73.4%) | ||||||
| Cash flow | — | — | — | — | — | — | (123.42) | (111.78) | (9.71) | (0.97) | (0.32) | (80.1%) | ||||||
| Capex | — | — | — | — | — | — | (12.89) | (1.72) | (0.09) | (0.01) | (0.01) | (91.5%) | ||||||
| Free cash flow | — | — | — | — | — | — | (136.30) | (113.50) | (9.81) | (0.98) | (0.33) | (80.7%) | ||||||
| Book value | — | — | — | — | — | — | 270.94 | 97.26 | 13.46 | 1.57 | 1.36 | (82.0%) | ||||||
| Shares, m | — | — | — | — | — | — | 0 | 0 | 5 | 30 | 62 | +359.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | 0.00 | 0.00 | 94.52 | 60.25 | 31.5 | ||||||
| P/B | — | — | — | — | — | — | — | 0.00 | 1.43 | 6.93 | 2.99 | 2.8 | ||||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | 0.00 | 62.84 | 36.71 | 20.9 | ||||||
| EV/FCF | — | — | — | — | — | — | — | (0.08) | (0.57) | (7.38) | (7.41) | (2.7) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (39) | (44) | (46) | (30) | (26) | (8.5%) | |||||
| Capex | — | — | — | — | — | — | (4) | (1) | 0 | 0 | (1) | (60.8%) | ||||||
| Free cash flow | — | — | — | — | — | — | (43) | (45) | (46) | (30) | (26) | (11.2%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | 76 | 32 | 57 | 99 | 108 | +8.8% | |||||
| Net debt | — | — | — | — | — | — | (83) | (38) | (64) | (111) | (125) | +10.1% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | 85 | 38 | 63 | 48 | 107 | (17.4%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (62.59) | (77.73) | (82.00) | (109.89) | (82.0) pt | |||||
| ROIC | — | — | — | — | — | — | (1,790.30) | (17,526.69) | 0.00 | 0.00 | 0.00 | +1,790.3 pt | ||||||
| ROE | — | — | — | — | — | — | 0.00 | 48.98 | 170.97 | (145.07) | (146.12) | (145.1) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 58 | 55 | 48 | — | (9.0%) | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.01 | 0.01 | 0.07 | — | +247.5% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026
CAMP4 Therapeutics Corporation vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| LCTX Lineage Cell Therapeutics, Inc. | $258.0M | — (loss-making) | — (loss-making) | −61.34% (below 0%: shrinking) | n/m | −32.40% (below 0%: shrinking) | 100.00% | (834.71%) | Compare |
| CAMP CAMP4 Therapeutics Corporation | $254.8M | — (loss-making) | — (loss-making) | +138.87% (above 0%: growing) | n/m | +20.36% (above 0%: growing) | 100.00% | (738.76%) | |
| LRMR Larimar Therapeutics, Inc. | $248.3M | — (loss-making) | — | — | n/m | −127.63% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| EVMN Evommune Inc. | $241.3M | — (loss-making) | — (loss-making) | — | n/m | +21.78% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ABEO Abeona Therapeutics Inc. | $238.5M | — (loss-making) | — (loss-making) | +225.14% (above 0%: growing) | n/m | +17.11% (above 0%: growing) | 63.30% | (119.97%) | Compare |
| IMRX Immuneering Corporation | $238.3M | — (loss-making) | — (loss-making) | −99.74% (below 0%: shrinking) | n/m | −40.19% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| LXEO Lexeo Therapeutics, Inc. | $237.2M | — (loss-making) | — (loss-making) | — | n/m | +35.58% (above 0%: growing) | 0.00% | 0.00% | Compare |
| VNDA Vanda Pharmaceuticals Inc. | $231.0M | — (loss-making) | — (loss-making) | +24.10% (above 0%: growing) | n/m | +9.57% (above 0%: growing) | 94.05% | (33.69%) | Compare |
| FATE Fate Therapeutics, Inc. | $223.1M | — (loss-making) | — (loss-making) | +9.18% (above 0%: growing) | n/m | +8.96% (above 0%: growing) | 100.00% | (1,495.39%) | Compare |
| Median of peers | $238.4M | — | — | +9.18% | — | +9.27% | 78.68% | (16.84%) |
Pay and ownership Proxy statement filed 23 April 2026
Ownership
Directors and executive officers, together
21.69%
Janus Henderson Group plc
12.15%
Entities affiliated with
11.30%
Andrew J. Schwab
11.30%
Coastlands Capital Partners LP
9.99%
Entities affiliated with FMR LLC
9.47%
Entities affiliated with Vivo Opportunity Fund
8.18%
Entities affiliated with Polaris Partners
7.57%
Amir Nashat, ScD
7.57%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement